Estimated Savings From International Reference Pricing for Prescription Drugs

Andrew W Mulcahy; Daniel Schwam; Preethi Rao; Stephanie Rennane; Kanaka Shetty

doi:10.1001/jama.2021.13338

Estimated Savings From International Reference Pricing for Prescription Drugs

JAMA. 2021 Nov 2;326(17):1744-1745. doi: 10.1001/jama.2021.13338.

Authors

Andrew W Mulcahy¹, Daniel Schwam¹, Preethi Rao¹, Stephanie Rennane¹, Kanaka Shetty²

Affiliations

¹ The RAND Corporation, Arlington, Virginia.
² The RAND Corporation, Santa Monica, California.

Abstract

This study estimates what 2020 national US savings would have been using international reference pricing rather than US manufacturer and net prices for insulins and 50 top brand-name drugs.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Cost Savings*
Drug Costs / legislation & jurisprudence*
Government Regulation
Internationality
Medicare / economics
Prescription Drugs / economics*
United States

Substances

Prescription Drugs